Boardroom Alpha
Boardroom Alpha
ANVS · Additional Proxy Materials (DEFA14A) · Filed April 30, 2026

Annovis Bio Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 30, 2026
Ticker
ANVS
Accession
0001104659-26-053130
Boardroom Alpha · Filing insights

Annovis Bio, Inc. outlines its 2026 meeting; board recommends FOR all nominees and Proposals 2-4, and 2-YEARS on Proposal 5.

About Annovis Bio Inc
Market cap
$64M
1Y TSR
−21.3%
3Y TSR
−46.9%
Board grade
C-
Sector
Healthcare
CEO
Maria-Luisa Maccecchini
Last annual meeting: Jun 17, 2026 · View full Annovis Bio Inc profile →

GRAPHIC

ANNOVIS BIO, INC. Mr AB Sample Sample Street Sample Town Sampleshire, XXX XXX Important Notice Regarding the Internet Availability of Proxy Materials for the Annual Meeting of Stockholders to be held virtually on June 17, 2026 at 10:00 a.m. ET This communication is not a form of voting and presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Proxy Statement and Annual Report are available at https://web.viewproxy.com/annovisbio/2026 If you want to receive a paper or e-mail copy of these documents, you must request one by following the instructions below on or before June 8, 2026 to facilitate timely delivery. There is no charge to you for requesting a copy. Important information regarding the Internet availability of the Company’s proxy materials, instructions for accessing your proxy materials and voting online, and instructions for requesting paper or e-mail copies of your proxy materials are outlined in this Notice. You must use the 11-digit Virtual Control Number located in the box to attend the Annual Meeting virtually, to vote via Internet, or to request proxy materials. CONTROL NUMBER STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE ANNUAL MEETING. To the Stockholders of Annovis Bio, Inc.: The 2026 Annual Meeting of Stockholders of Annovis Bio, Inc. will be held virtually on Wednesday, June 17, 2026 at 10:00 a.m. ET. In order to attend the meeting, you must register at https://web.viewproxy.com/annovisbio/2026 by 11:59 PM EDT on June 16, 2026. You will receive a meeting invitation by e-mail with your unique join link along with a password prior to the meeting date. Stockholders will be able to listen, vote and submit questions during the virtual meeting. Further instructions on how to attend and vote at the Annual Meeting of Stockholders are contained in the Proxy Statement in the section titled “Questions and Answers About the Proxy Materials and Our Annual Meeting - What do I need to do to attend the Annual Meeting virtually?”. The Board of Directors recommends a vote “FOR” all the nominees listed in Proposal 1, “FOR” Proposals 2, 3 and 4, and “2-YEARS” on Proposal 5. 1. ELECTION OF DIRECTORS: (1) Michael Hoffman (2) Maria Maccecchini (3) Claudine Bruck (4) Reid McCarthy (5) Mark White 2. To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 3. To approve an amendment to the Annovis Bio, Inc. 2019 Equity Incentive Plan (the “Option Plan”) 4. To approve an advisory (non-binding) proposal on our executive compensation 5. To approve an advisory (non-binding) proposal regarding the frequency with which stockholders should vote on our executive compensation Note: To transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.

GRAPHIC

Internet: Go to https://web.viewproxy.com/annovisbio/2026 Have the 11-digit Virtual Control Number available when you access the website and follow the instructions. Telephone: Call 1-877-777-2857 Toll Free E-Mail: By e-mail at: requests@viewproxy.com * If requesting material by e-mail, please send a blank e-mail with the company name and your 11-digit Virtual Control Number in the subject line. No other requests, instructions, or other inquiries should be included within this email request. The Securities and Exchange Commission rules permit us to make our proxy materials available to our stockholders via the Internet. Material for this Annual Meeting and future meetings may be requested by one of the following methods: Via Internet prior to the Annual Meeting: Go to https://www.web.viewproxy.com/annovisbio/2026 Have your 11-digit Virtual Control Number available and follow the prompts. • Your electronic vote prior to the Annual Meeting authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated, and returned a proxy card. Via Internet during the Annual Meeting: Go to https://www.web.viewproxy.com/annovisbio/2026 You must register in advance to attend the Annual Meeting and vote your shares. Have your 11-digit Virtual Control Number available during the Annual Meeting in order to vote. Via Telephone: Call 1-866-804-9616 Use any touch-tone telephone to vote your proxy. Have your 11-digit Control Number available. Follow the voting instructions to vote your shares. Via Mail: Follow the instructions above to request materials for this Annual Meeting which includes a proxy card. Follow the instructions on the proxy card for voting by mail. VOTING METHODS ANNOVIS BIO, INC. CONTROL NUMBER

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Annovis Bio Inc (ANVS)

Reference

Frequently asked questions

When did Annovis Bio Inc file this DEFA14A?
Annovis Bio Inc (ANVS) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 30, 2026. The accession number assigned by EDGAR is 0001104659-26-053130.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Annovis Bio, Inc. outlines its 2026 meeting; board recommends FOR all nominees and Proposals 2-4, and 2-YEARS on Proposal 5. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Annovis Bio Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Annovis Bio Inc has filed under CIK 1477845, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer